Literature DB >> 18855599

Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development.

Yan Li1, Guifang Huang, James Diakur, Leonard I Wiebe.   

Abstract

The asialoglycoprotein receptor (ASGPR), an endocytotic cell surface receptor expressed by hepatocytes, is triggered by triantennary binding to galactose residues of macromolecules such as asialoorosomucoid (ASOR). The capacity of this receptor to import large molecules across the cellular plasma membrane makes it an enticing target for receptor-mediated drug delivery to hepatocytes and hepatoma cells via ASGPR-mediated endocytosis. This study describes the preparation and characterization of (125)I-ASOR, and its utility in the assessment of ASGPR expression by HepG2, HepAD38 and Huh5-2 human hepatoma cell lines. ASOR was prepared from human orosomucoid, using acid hydrolysis to remove sialic acid residues, then radioiodinated using iodogen. (125)I-ASOR was purified by gel column chromatography and characterized by SDS-PAGE electrophoresis. The ASOR yield by acid hydrolysis was 75%, with approximately 87 % of the sialic acid residues removed. Electrophoresis and gel chromatography demonstrated substantial differences in (125)I-ASOR quality depending on the method of radioiodination. ASGPR densities per cell were estimated at 76,000 (HepG2), 17,000 (HepAD38) and 3,000 (Huh-5-2). (125)I-ASOR binding to ASGPR on HepG2 cells was confirmed through galactose- and EDTA- challenge studies. It is concluded that (125)I-ASOR is a facilely-prepared, stable assay reagent for ASGPR expression if appropriately prepared, and that HepG2 cells, but not HepAD38 or Huh-5-2 cells, are suitable for studies exploiting the endocytotic ASGPR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855599     DOI: 10.2174/156720108785915069

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  27 in total

Review 1.  Polymeric Nanostructures for Imaging and Therapy.

Authors:  Mahmoud Elsabahy; Gyu Seong Heo; Soon-Mi Lim; Guorong Sun; Karen L Wooley
Journal:  Chem Rev       Date:  2015-08-04       Impact factor: 60.622

2.  Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics.

Authors:  Jinjin Zhang; Jered C Garrison; Larisa Y Poluektova; Tatiana K Bronich; Natalia A Osna
Journal:  Biomaterials       Date:  2015-08-08       Impact factor: 12.479

3.  DNA-aptamer targeting vimentin for tumor therapy in vivo.

Authors:  Tatyana N Zamay; Olga S Kolovskaya; Yury E Glazyrin; Galina S Zamay; Svetlana A Kuznetsova; Ekaterina A Spivak; Mohamed Wehbe; Anna G Savitskaya; Olga A Zubkova; Anastasia Kadkina; Xiaoyan Wang; Darija Muharemagic; Anna Dubynina; Yuliya Sheina; Alla B Salmina; Maxim V Berezovski; Anna S Zamay
Journal:  Nucleic Acid Ther       Date:  2014-01-11       Impact factor: 5.486

4.  Capacity limits of asialoglycoprotein receptor-mediated liver targeting.

Authors:  Charlotte Bon; Thomas Hofer; Alain Bousquet-Mélou; Mark R Davies; Ben-Fillippo Krippendorff
Journal:  MAbs       Date:  2017-09-06       Impact factor: 5.857

5.  Liver-targeted delivery of liposome-encapsulated curcumol using galactosylated-stearate.

Authors:  Wen-Jie Li; You-Wen Lian; Quan-Sheng Guan; Ning Li; Wen-Jun Liang; Wen-Xin Liu; Yong-Bin Huang; Yi Cheng; Hui Luo
Journal:  Exp Ther Med       Date:  2018-05-23       Impact factor: 2.447

Review 6.  Enhancement of Curcumin Bioavailability Via the Prodrug Approach: Challenges and Prospects.

Authors:  Pahweenvaj Ratnatilaka Na Bhuket; Asma El-Magboub; Ian S Haworth; Pornchai Rojsitthisak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

7.  Pharmacokinetics of liver-targeted docetaxel liposomes modified with 6-O-acyl-D-galactose esters in rabbits.

Authors:  Wei Wu; Yi Cheng; Bo-Hong Guo; Qiong Wu
Journal:  Biomed Rep       Date:  2014-05-19

8.  Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing.

Authors:  Romain Rouet; Benjamin A Thuma; Marc D Roy; Nathanael G Lintner; David M Rubitski; James E Finley; Hanna M Wisniewska; Rima Mendonsa; Ariana Hirsh; Lorena de Oñate; Joan Compte Barrón; Thomas J McLellan; Justin Bellenger; Xidong Feng; Alison Varghese; Boris A Chrunyk; Kris Borzilleri; Kevin D Hesp; Kaihong Zhou; Nannan Ma; Meihua Tu; Robert Dullea; Kim F McClure; Ross C Wilson; Spiros Liras; Vincent Mascitti; Jennifer A Doudna
Journal:  J Am Chem Soc       Date:  2018-05-18       Impact factor: 15.419

9.  Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.

Authors:  Sandhya Pranatharthiharan; Mitesh D Patel; Vinod C Malshe; Vaishali Pujari; Ajit Gorakshakar; Manisha Madkaikar; Kanjaksha Ghosh; Padma V Devarajan
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 10.  Gene Therapies for Cancer: Strategies, Challenges and Successes.

Authors:  Swadesh K Das; Mitchell E Menezes; Shilpa Bhatia; Xiang-Yang Wang; Luni Emdad; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2015-02       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.